TY - JOUR
T1 - Nanoreporter PET predicts the efficacy of anti-cancer nanotherapy
AU - Pérez-Medina, Carlos
AU - Abdel-Atti, Dalya
AU - Tang, Jun
AU - Zhao, Yiming
AU - Fayad, Zahi A.
AU - Lewis, Jason S.
AU - Mulder, Willem J. M.
AU - Reiner, Thomas
PY - 2016
Y1 - 2016
N2 - The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (Zr-89-NRep) allows precise doxorubicin (DOX) quantification. Importantly, Zr-89-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. Zr-89-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with 425 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy
AB - The application of nanoparticle drug formulations, such as nanoliposomal doxorubicin (Doxil), is increasingly integrated in clinical cancer care. Despite nanomedicine's remarkable potential and growth over the last three decades, its clinical benefits for cancer patients vary. Here we report a non-invasive quantitative positron emission tomography (PET) nanoreporter technology that is predictive of therapeutic outcome in individual subjects. In a breast cancer mouse model, we demonstrate that co-injecting Doxil and a Zirconium-89 nanoreporter (Zr-89-NRep) allows precise doxorubicin (DOX) quantification. Importantly, Zr-89-NRep uptake also correlates with other types of nanoparticles' tumour accumulation. Zr-89-NRep PET imaging reveals remarkable accumulation heterogeneity independent of tumour size. We subsequently demonstrate that mice with 425 mg kg(-1) DOX accumulation in tumours had significantly better growth inhibition and enhanced survival. This non-invasive imaging tool may be developed into a robust inclusion criterion for patients amenable to nanotherapy
U2 - https://doi.org/10.1038/ncomms11838
DO - https://doi.org/10.1038/ncomms11838
M3 - Article
C2 - 27319780
SN - 2041-1723
VL - 7
SP - 11838
JO - Nature communications
JF - Nature communications
ER -